Michael Gwarisa As more African countries begin to introduce lenacapavir into their HIV prevention programmes, scientists are examining new data showing that a small number of people became infected with HIV while using the medication. The drug’s rollout now extends beyond just one or two nations. Countries that have started distributing the twice-yearly injectable or